Targeting of the PD-1/PD-L1 (programmed cell death-ligand 1) immunosuppressive pathway combined with CD73 inhibitors may provide additional clinical benefits and partially overcome primary and secondary drug resistance to PD-1/PD-L1 blockade, as well as put forward a strong theoretical basis for precise immunotherapy and further the development of CD73 immunotherapy strategies for DLBCL patients. This evidence concerns the gene NT5E and diffuse large B-cell lymphoma.